Skip to main content

Peer Review reports

From: Patients with metastatic renal cell carcinoma who receive immune-targeted therapy may derive survival benefit from nephrectomy

Original Submission
3 Jan 2023 Submitted Original manuscript
Resubmission - Version 2
Submitted Manuscript version 2
Resubmission - Version 3
Submitted Manuscript version 3
Resubmission - Version 4
Submitted Manuscript version 4
24 Apr 2023 Reviewed Reviewer Report - Kazuhiro Yoshimura
5 May 2023 Reviewed Reviewer Report
12 Jun 2023 Reviewed Reviewer Report
19 Jun 2023 Author responded Author comments - Zhe Sun
Resubmission - Version 5
19 Jun 2023 Submitted Manuscript version 5
18 Jul 2023 Author responded Author comments - Zhe Sun
Resubmission - Version 6
18 Jul 2023 Submitted Manuscript version 6
19 Jul 2023 Author responded Author comments - Zhe Sun
Resubmission - Version 7
19 Jul 2023 Submitted Manuscript version 7
24 Jul 2023 Reviewed Reviewer Report
5 Aug 2023 Reviewed Reviewer Report
20 Aug 2023 Author responded Author comments - Zhe Sun
Resubmission - Version 8
20 Aug 2023 Submitted Manuscript version 8
8 Sep 2023 Reviewed Reviewer Report
12 Sep 2023 Author responded Author comments - Zhe Sun
Resubmission - Version 9
12 Sep 2023 Submitted Manuscript version 9
Publishing
16 Sep 2023 Editorially accepted
6 Oct 2023 Article published 10.1186/s12885-023-11408-x

You can find further information about peer review here.

Back to article page